Liver cancer

Merck gets FDA okay for Keytruda as liver cancer therapy

https://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/

EU regulators back Ipsen cancer drug in new liver cancer use

https://pharmaphorum.com/news/eu-regulators-cabometyx-liver/

Eisai/Merck & Co’s Lenvima approved in EU for first line liver cancer

https://pharmaphorum.com/news/eisai-merck-cos-lenvima-approved-in-eu-for-first-line-liver-cancer/

Raising the bar in liver cancer therapy

https://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/

Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s success

https://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/

Ipsen aims for new liver cancer use of Cabometyx

https://pharmaphorum.com/news/ipsen-aims-new-liver-cancer-use-cabometyx/

Introducing the 9th Annual RNA Therapeutics 2018

https://pharmaphorum.com/partner-content-oncology/introducing-the-9th-annual-rna-therapeutics-2018/

https://pharmaphorum.com/events/rna-therapeutics-2018/

Bayer’s Stivarga fast-tracked for liver cancer review

https://pharmaphorum.com/news/bayers-stivarga-fast-tracked-liver-cancer-review/

1 2

Close in 10 seconds

Pharmaphorum.com

Search